Laura Wagner, M.Sc.

Clinical Strategy Manager
Valneva Austria GmbH, Austria

Disclosure(s): Valneva: employee

Poster(s):

• (P-599) 6-Valent, OspA-Based VLA15 Lyme Disease Vaccine Candidate Against Lyme Borreliosis in a Healthy Pediatric and Adult Study Population: A Phase 2 Study Update
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT